Skip to contentP
Phathom Pharmaceuticals, Inc.
P
PHATPhathom Pharmaceuticals, Inc. Q1 2024 · 10-Q
Revenue$1.91M$1.91M— vs Q1 2023 Net Income-$82.85M-$82.85MN/M vs Q1 2023 EPS Diluted-$1.42-$1.42N/M vs Q1 2023 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Phathom Pharmaceuticals, Inc. · CIK 1783183 · Engraved from SEC EDGAR
Operating Cash Flow-$69,020,000N/M Free Cash Flowderived-$69,060,000N/M Margins · derivedGross margin77.7%
Operating margin-3658.7%
Net margin-4333.3%
ended Mar 31, 2024 · filed May 9, 2024 · 39 d after period end